GAM
NBIX icon

Gotham Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Gotham Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.6M Buy
371,568
+11,432
+3% +$1.7M 0.15% 109
2026
Q1 		$47.4M Buy
360,136
+191,564
+114% +$25.4M 0.15% 129
2025
Q4 		$23.9M Buy
168,572
+32,218
+24% +$4.67M 0.09% 314
2025
Q3 		$19.1M Buy
136,354
+45,225
+50% +$6.13M 0.08% 334
2025
Q2 		$11.5M Buy
91,129
+60,106
+194% +$6.89M 0.07% 427
2025
Q1 		$3.43M Buy
31,023
+25,309
+443% +$3.21M 0.03% 634
2024
Q4 		$780K Sell
5,714
-9,603
-63% -$1.19M 0.01% 988
2024
Q3 		$1.76M Sell
15,317
-22,962
-60% -$3.15M 0.02% 760
2024
Q2 		$5.27M Buy
38,279
+32,975
+622% +$4.52M 0.07% 413
2024
Q1 		$732K Sell
5,304
-234
-4% -$32K 0.01% 935
2023
Q4 		$730K Buy
5,538
+480
+9% +$55.3K 0.01% 875
2023
Q3 		$569K Sell
5,058
-355
-7% -$37.4K 0.01% 940
2023
Q2 		$510K Sell
5,413
-2,180
-29% -$213K 0.01% 963
2023
Q1 		$769K Sell
7,593
-236
-3% -$24.6K 0.02% 822
2022
Q4 		$935K Buy
7,829
+2,204
+39% +$258K 0.03% 703
2022
Q3 		$597K Buy
5,625
+29
+0.5% +$2.94K 0.02% 810
2022
Q2 		$545K Sell
5,596
-1,427
-20% -$132K 0.02% 759
2022
Q1 		$658K Buy
7,023
+4,465
+175% +$378K 0.02% 706
2021
Q4 		$218K Buy
+2,558
New +$235K 0.01% 1055
2020
Q4 		– Sell
-18,712
Closed -$1.8M – 1069
2020
Q3 		$1.8M Buy
18,712
+5,870
+46% +$679K 0.06% 386
2020
Q2 		$1.57M Sell
12,842
-6,363
-33% -$703K 0.05% 457
2020
Q1 		$1.66M Sell
19,205
-10,460
-35% -$1.02M 0.05% 445
2019
Q4 		$3.19M Buy
29,665
+15,730
+113% +$1.65M 0.06% 366
2019
Q3 		$1.26M Buy
13,935
+3,431
+33% +$321K 0.02% 540
2019
Q2 		$887K Sell
10,504
-8,828
-46% -$725K 0.01% 658
2019
Q1 		$1.7M Buy
19,332
+2,956
+18% +$247K 0.02% 525
2018
Q4 		$1.17M Sell
16,376
-7,246
-31% -$694K 0.02% 601
2018
Q3 		$2.9M Buy
23,622
+16,209
+219% +$1.84M 0.04% 438
2018
Q2 		$728K Buy
+7,413
New +$664K 0.01% 631

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gotham Asset Management's NBIX Position: Q2 2026 in Review

Gotham Asset Management increased its Neurocrine Biosciences (NBIX) stake by 3.2% in Q2 2026, buying an estimated $1.7M and bringing the position to 371,568 shares worth $62.6M. The position accounts for 0.15% of the portfolio, ranked #109.

Gotham Asset Management first reported a position in NBIX in Q2 2018 and has held it in 29 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Gotham Asset Management held 371,568 shares of Neurocrine Biosciences worth $62.6M as of Q2 2026.
  • Gotham Asset Management bought 11,432 Neurocrine Biosciences shares in Q2 2026, an estimated $1.7M.
  • Neurocrine Biosciences made up 0.15% of Gotham Asset Management's portfolio in Q2 2026, its #109 holding.
  • Gotham Asset Management first reported a position in Neurocrine Biosciences in Q2 2018 and has held it in 29 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.